Browse by author
Lookup NU author(s): Dr Joyce Nutt, Henry Lazarowicz, Kilian Mellon, Professor John LunecORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The effect of EGF stimulation and its inhibition with gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been investigated in two EGFR-positive human bladder tumour cell lines, RT112 and RT4. The growth of RT112 cells in a medium containing 10% foetal bovine serum was inhibited by 50% with 10 μM gefitinib, whereas this dose completely inhibited RT4 cell growth. Cells were more sensitive to growth inhibition in the serum-free medium. Increased growth of cells in the serum-free medium was observed with 10 or 50 ng ml-1 EGF and the proliferative effect of EGF stimulation in both cell lines was inhibited in the presence of 1 μM, but not 0.1 μM gefitinib. Zymography of the conditioned medium from RT112 cells treated with EGF and gefitinib showed a decrease in matrix metalloproteinase 2 (MMP2) concentrations. Western blot analysis showed that tissue inhibitor of metalloproteinase 1 (TIMP1) increased in the conditioned medium from RT112 cells treated with EGF, and this was partially inhibited with both 1 and 5 μM gefitinib. Conversely, TIMP2 decreased with EGF stimulation and this was reversed with gefitinib. Tissue inhibitor of metalloproteinase 1 had no effect on the growth of either cell line. These studies show alterations in the balance of MMPs and their inhibitors in EGF-stimulated bladder tumour cells, which are reversed by gefitinib, suggesting gefitinib should be investigated for its effect on human bladder tumours. © 2004 Cancer Research UK.
Author(s): Nutt, J., Lazarowicz, H., Mellon, J., Lunec, J.
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 2004
Volume: 90
Issue: 8
Pages: 1679-1685
Print publication date: 19/04/2004
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
URL: http://dx.doi.org/10.1038/sj.bjc.6601768
DOI: 10.1038/sj.bjc.6601768
PubMed id: 15083203
Altmetrics provided by Altmetric
